Answers are grounded in this paper and cite their sources.
Background/Objectives: Oral squamous cell carcinoma often arises from oral leukoplakia, a precancerous lesion. Distinguishing malignant transformation from leukoplakia currently relies on repeated, invasive biopsies. A noninvasive method to discriminate OSCC from leukoplakia is needed. Fatty acid metabolic reprogramming in cancers alters serum free fatty acid (FFA) profiles. We aimed to identify serum FFAs that distinguish OSCC from leukoplakia. Methods: The gene expression of fatty acid metabolizing enzymes in leukoplakia and OSCC tissues was assessed using a public microarray dataset. Serum levels of 21 FFAs were quantified by liquid chromatography–tandem mass spectrometry in 68 healthy donors, 26 patients with leukoplakia, and 38 patients with OSCC. Results: Fatty acid metabolizing enzyme genes were differentially expressed between leukoplakia and OSCC tissues, with upregulation of genes involved in de novo synthesis and downregulation of those involved in fatty acid uptake and lipolysis. Seven serum FFAs were significantly altered in OSCC from the early stage, whereas serum FFA levels in healthy donors were comparable to those in leukoplakia. Three of the altered FFAs—stearic acid, arachidic acid, and lauric acid—each discriminated OSCC from leukoplakia with high accuracy as single markers (area under the curve > 0.9), independently of clinical stage, age, and smoking history. Lauric acid was effective across the full clinical spectrum and the least affected by body composition, making it the most suitable for practical implementation. Conclusions: Serum FFA profiling represents a promising noninvasive strategy for the early detection of OSCC, with the potential to complement biopsy in the surveillance of leukoplakia.
No takes yet. Share an insight, caveat, or question.
Fujii et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: